Journal of Enzyme Inhibition and Medicinal Chemistry · 2018 · 110 citations · 47 references
MedicineMedicinal ChemistryPharmacologyApoptosisCancer PharmacologyDrug DiscoveryApoptosis PharmacologyPharmacodynamics Of Anticancer AgentsAnti-apoptotic AgentsAnticancer ActivityApoptosis TargetingBcl2 InhibitionCancer Cell Proliferation InhibitionIn-vitro Characterization
= 3.48 ± 0.28 and 5.03 ± 0.39 µM, respectively). Compounds 13a and 15a were able to induce apoptosis in HepG2 cells, as assured by the upregulation of the Bax and downregulation of the Bcl-2, besides boosting caspase-3 levels. Besides, compound 13a induced a significant increase in the percentage of cells at Pre-G1 by 6.4-folds, with concurrent significant arrest in the G2-M phase by 5.4-folds compared to control. Also, 13a displayed significant increase in the percentage of annexin V-FITC positive apoptotic cells from 1.75-13.76%. Moreover, QSAR models were established to explore the structural requirements controlling the anti-proliferative activities.
47
New Colorimetric Cytotoxicity Assay for Anticancer-Drug Screening
Philip Skehan, Ritsa Storeng, Dominic A. Scudiero et al. · JNCI Journal of the National Cancer Institute · 1990 · 9.8K citations
Medicine, Oncology, Pharmacology +10
Cancer treatment and survivorship statistics, 2016
Kimberly D. Miller, Rebecca L. Siegel, Chun Chieh Lin et al. · CA A Cancer Journal for Clinicians · 2016 · 6.2K citations · Full text
Arup K. Ghose, Gordon M. Crippen · Journal of Chemical Information and Computer Sciences · 1987 · 808 citations
Arup K. Ghose, Gordon M. Crippen · Journal of Computational Chemistry · 1986 · 627 citations · Full text